Dr Ulrike Lorch

Dr Ulrike Lorch co-founded Richmond Pharmacology in 2001 and serves as Chief Operating Officer and Principal Investigator for early phase clinical trials. Her expertise centres on the design and conduct of first-in-human and other early phase trials, including those involving patients with rare diseases and advanced therapeutic modalities such as in-vivo gene editing and gene silencing. Her approach emphasises adaptive trial design and continuous process optimisation, employing customisable standards and guidelines to accelerate access to effective treatments.

As Chief Medical Director, she oversees clinical safety across all trials conducted by Richmond Pharmacology. Since its inception, the organisation has consistently maintained Phase 1 accreditation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Ulrike is a Fellow of both the Royal College of Anaesthetists and the Faculty of Pharmaceutical Medicine, and she holds UK Board Certification in Pharmaceutical Medicine. In her role as Appraisal Lead and Educational Supervisor, she supports training, revalidation, and Board Certification for physicians. Richmond Pharmacology is a General Medical Council-accredited site for postgraduate training and revalidation.

‍